1. Imaging minimal residual disease evaluation in multiple myeloma using [18F]FDG PET/MRI.
- Author
-
Barilà, Gregorio, Crimì, Filippo, Arangio Febbo, Massimiliano, Pavan, Laura, Vedovato, Susanna, Cabrelle, Giulio, Zanon, Chiara, Campi, Cristina, Cecchin, Diego, Zucchetta, Pietro, Lacognata, Carmelo, Semenzato, Gianpietro, and Zambello, Renato
- Subjects
MULTIPLE myeloma ,POSITRON emission tomography computed tomography ,MAGNETIC resonance imaging ,MONOCLONAL gammopathies ,PLASMACYTOMA - Abstract
Certainly, availability of PET/MRI device is limited to few centers, in addition, this imaging technique is burdened by longer imaging acquisition time and higher costs with respect to PET/CT or WB-DWI-MRI. Therefore, patients achieving both PET/CT and WB-DWI-MRI negativity after treatment showed improved PFS as compared to patients with residual disease by PET or MRI [[9]]. Regarding baseline PET/MRI evaluation, FLs were detected in 23 patients, with mean SUVmax of 4.4 ± 2.78 and mean ADC of 963 ± 264.6 mm SP 2 sp /s. At the end of treatment PET/MRI showed a PET negativity (DS <= 3) in 23/27 (85.2%) patients, a MRI negativity (RAC = 1) in 18/27 (66.7%) cases and a concomitant PET and MRI negativity (DS <= 3 and RAC = 1) in 18/27 (66.7%) cases. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF